argenx
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- argenx
- Target Recruit Count
- 72
- Registration Number
- NCT06968338
- Locations
- 🇨🇦
Altasciences, Montréal, Canada
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Conditions
- Chronic Inflammatory Demyelinating PolyneuropathyCIDP - Chronic Inflammatory Demyelinating PolyneuropathyCIDP
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- argenx
- Target Recruit Count
- 218
- Registration Number
- NCT06920004
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
- Conditions
- New Onset Generalized Myasthenia Gravis (gMG)
- Interventions
- Biological: Efgartigimod PH20 SC
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- argenx
- Target Recruit Count
- 30
- Registration Number
- NCT06909214
A Study to Assess the Safety of ARGX-109 in Healthy Volunteers
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- argenx
- Target Recruit Count
- 32
- Registration Number
- NCT06799416
- Locations
- 🇨🇦
Altasciences - Montreal - Phase I unit, Mount-Royal, Quebec, Canada
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
- Conditions
- Multifocal Motor Neuropathy (MMN)
- Interventions
- Biological: IVIG (Intravenous Immunoglobulin)Other: IVIg-placeboOther: Empasiprubart-placebo
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- argenx
- Target Recruit Count
- 100
- Registration Number
- NCT06742190
- Locations
- 🇺🇸
The Neurology Group, Pomona, California, United States
🇺🇸Medstar Health Research Institute, Washington, District of Columbia, United States
🇺🇸Healthcare Innovations Institute, LLC, Coral Springs, Florida, United States
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome
- Conditions
- Primary Sjogrens Disease
- Interventions
- Biological: Efgartigimod PH20 SCOther: Placebo PH20 SC
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- argenx
- Target Recruit Count
- 580
- Registration Number
- NCT06684847
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Chicago Clinical Research Institute, Chicago, Illinois, United States
🇺🇸Accurate Clinical Research Inc., Lake Charles, Louisiana, United States
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- Conditions
- Systemic Sclerosis (SSc)
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- argenx
- Target Recruit Count
- 81
- Registration Number
- NCT06655155
- Locations
- 🇵🇷
The Alliance Medical Sciences Campus, San Juan, Puerto Rico
🇨🇭Kantonsspital St. Gallen, Sankt Gallen, Switzerland
🇺🇸Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, United States
A Study to Assess Adults with CIDP Transitioning from IVIg to Efgartigimod PH20 SC
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Biological: Efgartigimod PH20 SC
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 25
- Registration Number
- NCT06637072
- Locations
- 🇺🇸
Neurology Associates PA, Maitland, Florida, United States
🇺🇸Visionary Investigators Network, Miami, Florida, United States
🇺🇸National Neuromuscular Research Institute, Austin, Texas, United States
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- Conditions
- Myasthenia Gravis, Ocular
- Interventions
- Combination Product: Efgartigimod PH20 SCOther: Placebo PH20 SC
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- argenx
- Target Recruit Count
- 124
- Registration Number
- NCT06558279
- Locations
- 🇧🇪
Hôpital de la Citadelle, Liège, Belgium
🇺🇸Neurology Offices of South Florida, Boca Raton, Florida, United States
🇺🇸SFM Clinical Research, LLC, Boca Raton, Florida, United States
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Conditions
- Primary Immune Thrombocytopenia (ITP)
- Interventions
- Biological: Efgartigimod IVOther: Placebo IV
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- argenx
- Target Recruit Count
- 63
- Registration Number
- NCT06544499
- Locations
- 🇺🇸
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇦🇹Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria
🇮🇪St James's Hospital - Cancer Clinical Trials Office, Dublin, Ireland